Ricoh Exits 3D Printed Healthcare With Myrava Acquisition

Ricoh 3D for Healthcare Sold to Myrava

Ricoh USA has completed the sale of its Ricoh 3D for Healthcare business to Myrava, Inc., a company focused on personalized medical devices and healthcare innovations across the United States. The deal hands the reins of a division that Ricoh launched less than two years ago to a team that already knows it intimately.

Gary Turner, CEO of Myrava, previously served as Vice President and General Manager of Ricoh 3D for Healthcare, LLC. That continuity matters. "Ricoh took an important step last year by establishing Ricoh 3D for Healthcare as a standalone entity, creating the focus and structure needed to serve a highly specialized and rapidly growing market," Turner said in a statement. "This acquisition is a natural next step in that evolution."

Why Ricoh Walked Away

The company's reasoning is plain: patient-specific medical devices require specialized capabilities that sit outside Ricoh's core strengths in office technology, process automation, and managed print services. Bob Lamendola, Ricoh USA's Chief Digital Services and Delivery Officer, put it directly: "While healthcare remains a key growth area for Ricoh, patient-specific medical devices require specialized capabilities that extend beyond the scope of our broader business priorities."

That is corporate language for "this was not our business." Ricoh set up the unit in 2025 after running it as an internal 3D medical manufacturing center. The separation took roughly a year before the sale became the obvious move.

What Myrava Plans to Do

Myrava intends to keep the team intact and push into FDA-cleared, point-of-care manufacturing. The pitch is that dedicated ownership will unlock investment that Ricoh's broader corporate structure could not justify. Personalized implants and surgical guides are the core products. Both markets are growing, but they also require regulatory expertise and deep clinical relationships that are hard to build quickly.

Turner's track record at Ricoh 3D for Healthcare gives Myrava a running start. The acquisition is structured as a clean handover rather than a fire sale, which suggests both sides consider the underlying business sound.

A Pattern in Corporate 3D Healthcare

Ricoh is not the first large technology company to step into 3D printed medical devices and then recalibrate. The sector demands regulatory patience, clinical sales cycles, and manufacturing precision that differ sharply from consumer hardware. Companies that approach it as a side bet tend to exit. Specialist operators like Myrava are usually the ones that stay.

The deal will likely be closely watched by other healthcare systems exploring in-house 3D implant production. Myrava's success or failure as an independent company will say a lot about whether the patient-specific medical device market is ready to stand on its own without corporate backing.

For now, the business Ricoh built gets a second life under new ownership with a leader who already knows the operation. That is a cleaner outcome than most corporate exits in this space.